This website is intended for US healthcare professionals.

Real EKTERLY® (sebetralstat) patient Zach talking on the phone Real EKTERLY® (sebetralstat) patient Zach talking on the phone
Real EKTERLY patient

Personalized support your patients can
count on

KalVista CaresTM is a support program for patients prescribed EKTERLY, helping them every step of the way during treatment.

  • Umbrella

    Benefits investigation & Prior Authorization
    Evaluate your patients’ insurance coverage, and assist with prior authorization requests, reauthorizations, and appeals to help secure coverage for EKTERLY

  • Insurance card

    Financial assistance options
    If your patients are eligible,
    our Care Managers can also help them
    enroll in the KalVista Cares Co-Pay Assistance Program*

  • Conversation bubbles

    Resources and community connections
    KalVista Cares is committed to empowering your patients by connecting them to valuable community and emotional support resources

  • Resources

    Specialty pharmacy coordination
    and triage
    We’ll work with the pharmacy and your patients’ insurance to help ensure smooth access to EKTERLY

  • QuickStart

    QuickStart program
    KalVista Cares may help patients with temporary treatment options while awaiting coverage determination or transitioning between insurance plans

Access when it matters most

KalVista Cares helps ensure that your patients will have consistent, reliable access
to EKTERLY when they
need it most

  • KalVista Cares Co-Pay Card
  • With the KalVista Cares Co-Pay Assistance Program,
    commercially insured patients may pay
    as little as $0 for their EKTERLY.*

To be eligible, patients must:

  • Have commercial insurance
    (commercial insurance does not include Medicare, Medicaid, Veterans
    Affairs [VA], or other federal or state health plans)
  • Be enrolled in the KalVista Cares
    Patient Support Program
  • Patient assistance program

    Patient assistance program
    KalVista Cares can provide your eligible patients with information about
    financial assistance

*This co-pay assistance program is intended only for eligible patients with commercial (private) insurance. Patients with government-funded insurance, such as Medicare, Medicaid, TRICARE, or any state or federal health insurance program, are not eligible to participate. Participation in the program is subject to eligibility requirements and program limits. The program may cover a portion or all of the patient’s out-of-pocket costs, up to a maximum amount determined by the program. Terms and conditions may change or the program may be discontinued at any time without notice. By participating, patients agree to comply with all terms and conditions.

Learn more about specific services provided by KalVista Cares

Download brochure download icon

Two ways to enroll
your patient

Select your preferred option below.

Complete your Start
Form online

Enroll online link icon

Fax completed Start Form
to 1‑844‑432‑9525

Download Start Form download icon Descargar Formulario download icon

Questions about the KalVista Cares Patient Support program?
Our team is available for assistance
Monday-Friday between
8:30 am-8 pm ET,
at 1‑844‑432‑3322

Real EKTERLY® (sebetralstat) patient Cari enjoying time with family Real EKTERLY® (sebetralstat) patient Cari enjoying time with family Real EKTERLY patient
UP NEXT:
ResourcesRight arrow

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache (3.2%).

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at 1-855-258-4782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.